Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1705229

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1705229

Keytruda Global Market Report 2025

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 4490
PDF (Site License)
USD 6490
PDF (Enterprise License)
USD 8490

Add to Cart

Keytruda, also known as pembrolizumab, is a monoclonal antibody medication utilized in cancer treatment. It falls under the category of immune checkpoint inhibitors, working by targeting and blocking the PD-1 (programmed cell death protein 1) protein in immune cells. This action assists the immune system in recognizing and attacking cancer cells effectively.

Keytruda is primarily used in treating various cancer types, including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma. Melanoma, specifically, is a type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment giving skin its color. The medication is available through different payer types such as commercial, Medicare, and Medicaid, and distributed through various channels such as hospital pharmacies and specialty pharmacies.

The keytruda market research report is one of a series of new reports from The Business Research Company that provides keytruda market statistics, including keytruda industry global market size, regional shares, competitors with a keytruda market share, detailed keytruda market segments, market trends and opportunities, and any further data you may need to thrive in the keytruda industry. This keytruda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The keytruda market size has grown rapidly in recent years. It will grow from $21.6 billion in 2024 to $23.8 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to improved patient outcomes, increased adoption of immunotherapy, research and development, improved patient compliance, and increased adoption of keytruda.

The keytruda market size is expected to see strong growth in the next few years. It will grow to $34.61 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expanding indications, emerging markets, increasing prevalence of cancer, rising healthcare expenditure, and growing demand for precision medicine. Major trends in the forecast period include demand for targeted therapies, advances in immunotherapy, advances in diagnostic technologies, demand for cancer treatment, and advances in cancer research.

The rising prevalence of cancer is expected to drive the growth of the Keytruda market in the coming years. Cancer is a complex set of diseases marked by the abnormal growth and spread of cells. Various factors, including genetics, lifestyle, environment, and hormones, contribute to the rising incidence of cancer. Keytruda (pembrolizumab) aids in cancer treatment by utilizing the body's immune system to more effectively combat cancer cells. It represents a major breakthrough in cancer therapy by empowering the immune system to target and destroy cancer cells, offering new hope for patients with advanced or metastatic cancers. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that cancer cases had increased to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth rate of 2.19%. Therefore, the growing prevalence of cancer is driving the expansion of the Keytruda market.

Leading companies in the Keytruda market are focused on developing innovative products such as pembrolizumab to expand treatment options. Pembrolizumab, a monoclonal antibody medication belonging to immune checkpoint inhibitors, is marketed under the brand name Keytruda. It targets and inhibits a protein called PD-1 (programmed cell death protein 1) on immune cells known as T cells. For instance, in November 2023, Merck, a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy approved by the Food and Drug Administration (FDA). This combination therapy has shown significant improvements in overall survival and progression-free survival compared to chemotherapy alone, presenting a promising advancement in gastric cancer treatment. Clinical trials have demonstrated enhancements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to standalone chemotherapy.

In May 2024, CytomX Therapeutics, a US-based biotechnology company, partnered with Merck to assess CX-801 with KEYTRUDA (pembrolizumab) in patients with advanced metastatic solid tumors. This collaboration aims to evaluate the safety, tolerability, and preliminary efficacy of CX-801 in combination with KEYTRUDA for advanced metastatic solid tumors. Merck, a US-based company, offers Keytruda as part of its pharmaceutical portfolio.

Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.

North America was the largest region in the keytruda market in 2024. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the keytruda market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The keytruda market consists of sales of immunotherapy, combination therapies, clinical trials, and personalized medicine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Keytruda Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on keytruda market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for keytruda ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The keytruda market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Cancer Type: Melanoma; Lung Cancer; Head And Neck Cancer; Hodgkin Lymphoma; Stomach Cancer; Urothelial Carcinoma
  • 2) By Payer Type: Commercial; Medicare; Medicaid
  • 3) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
  • Subsegments:
  • 1) By Melanoma: Advanced Or Unresectable Melanoma; Adjuvant Treatment For Melanoma
  • 2) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
  • 3) By Head And Neck Cancer: Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Recurrent Or Metastatic Head And Neck Cancer
  • 4) By Hodgkin Lymphoma: Classical Hodgkin Lymphoma; Relapsed Or Refractory Hodgkin Lymphoma
  • 5) By Stomach Cancer: Advanced Or Metastatic Gastric Cancer; Esophagogastric Junction Cancer
  • 6) By Urothelial Carcinoma: Advanced Or Metastatic Urothelial Carcinoma; Muscle-Invasive Bladder Cancer
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.
Product Code: r30536

Table of Contents

1. Executive Summary

2. Keytruda Market Characteristics

3. Keytruda Market Trends And Strategies

4. Keytruda Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Keytruda Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Keytruda PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Keytruda Market Growth Rate Analysis
  • 5.4. Global Keytruda Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Keytruda Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Keytruda Total Addressable Market (TAM)

6. Keytruda Market Segmentation

  • 6.1. Global Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Melanoma
  • Lung Cancer
  • Head And Neck Cancer
  • Hodgkin Lymphoma
  • Stomach Cancer
  • Urothelial Carcinoma
  • 6.2. Global Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Commercial
  • Medicare
  • Medicaid
  • 6.3. Global Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Specialty Pharmacies
  • 6.4. Global Keytruda Market, Sub-Segmentation Of Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Advanced Or Unresectable Melanoma
  • Adjuvant Treatment For Melanoma
  • 6.5. Global Keytruda Market, Sub-Segmentation Of Lung Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
  • 6.6. Global Keytruda Market, Sub-Segmentation Of Head And Neck Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
  • Recurrent Or Metastatic Head And Neck Cancer
  • 6.7. Global Keytruda Market, Sub-Segmentation Of Hodgkin Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Classical Hodgkin Lymphoma
  • Relapsed Or Refractory Hodgkin Lymphoma
  • 6.8. Global Keytruda Market, Sub-Segmentation Of Stomach Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Advanced Or Metastatic Gastric Cancer
  • Esophagogastric Junction Cancer
  • 6.9. Global Keytruda Market, Sub-Segmentation Of Urothelial Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Advanced Or Metastatic Urothelial Carcinoma
  • Muscle-Invasive Bladder Cancer

7. Keytruda Market Regional And Country Analysis

  • 7.1. Global Keytruda Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Keytruda Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Keytruda Market

  • 8.1. Asia-Pacific Keytruda Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Keytruda Market

  • 9.1. China Keytruda Market Overview
  • 9.2. China Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Keytruda Market

  • 10.1. India Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Keytruda Market

  • 11.1. Japan Keytruda Market Overview
  • 11.2. Japan Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Keytruda Market

  • 12.1. Australia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Keytruda Market

  • 13.1. Indonesia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Keytruda Market

  • 14.1. South Korea Keytruda Market Overview
  • 14.2. South Korea Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Keytruda Market

  • 15.1. Western Europe Keytruda Market Overview
  • 15.2. Western Europe Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Keytruda Market

  • 16.1. UK Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Keytruda Market

  • 17.1. Germany Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Keytruda Market

  • 18.1. France Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Keytruda Market

  • 19.1. Italy Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Keytruda Market

  • 20.1. Spain Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Keytruda Market

  • 21.1. Eastern Europe Keytruda Market Overview
  • 21.2. Eastern Europe Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Keytruda Market

  • 22.1. Russia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Keytruda Market

  • 23.1. North America Keytruda Market Overview
  • 23.2. North America Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Keytruda Market

  • 24.1. USA Keytruda Market Overview
  • 24.2. USA Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Keytruda Market

  • 25.1. Canada Keytruda Market Overview
  • 25.2. Canada Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Keytruda Market

  • 26.1. South America Keytruda Market Overview
  • 26.2. South America Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Keytruda Market

  • 27.1. Brazil Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Keytruda Market

  • 28.1. Middle East Keytruda Market Overview
  • 28.2. Middle East Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Keytruda Market

  • 29.1. Africa Keytruda Market Overview
  • 29.2. Africa Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Keytruda Market Competitive Landscape And Company Profiles

  • 30.1. Keytruda Market Competitive Landscape
  • 30.2. Keytruda Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Keytruda Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Novartis AG
  • 31.3. AstraZeneca PLC
  • 31.4. Bristol-Myers Squibb Company
  • 31.5. Eli Lilly and Company
  • 31.6. Amgen Inc.
  • 31.7. Gilead Sciences Inc.
  • 31.8. Teva Pharmaceutical Industries Ltd.
  • 31.9. Biogen Inc.
  • 31.10. Chugai Pharmaceutical Co. Ltd.
  • 31.11. BioNTech AG
  • 31.12. Organon Co.
  • 31.13. Ono Pharmaceutical Co. Ltd.
  • 31.14. Samsung Bioepis Co. Ltd.
  • 31.15. Fate Therapeutics Inc.

32. Global Keytruda Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Keytruda Market

34. Recent Developments In The Keytruda Market

35. Keytruda Market High Potential Countries, Segments and Strategies

  • 35.1 Keytruda Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Keytruda Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Keytruda Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!